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SUMMARY
Musculoskeletal conditions are the most frequent cause of chronic pain and affect around 1 in 5 adults in 
Europe. When chronic pain occurs, it becomes disease itself, with substantial clinical, social and economic 
impact. Effi cacy and tolerability problems are encountered with all therapeutic strategies available to treat mus-
culoskeletal pain. This often limits effective analgesia and patients’ long term compliance, with the result that 
chronic pain is persistently underestimated and undertreated. Tapentadol is a novel, centrally acting analgesic 
that has been recently commercialized for the treatment of chronic pain. This new molecule, by combining two 
distinct mechanisms of action, μ-opioid receptor agonism (MOR) and noradrenaline reuptake inhibition (NRI), 
introduces a new pharmacological class called MOR-NRI. Several studies demonstrated promising results in 
the management of both nociceptive and neuropathic pain and good tolerability profi le, particularly concerning 
side effects, compared to traditional opioids. This novel analgesic represents a possible therapeutic option also 
in the rheumatologic fi eld, particularly in the treatment of osteoarthritis and low back pain.
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Musculoskeletal diseases represent a clinically and socio-economically 
relevant issue involving hundreds of mil-
lion of people around the world (1). The 
burden of these conditions can be further 
increased when severe long-term pain oc-
curs. Prolonged triggers result in activation 
of the pain matrix in the brain and neuronal 
plasticity with the result that pain percep-
tion can be elicitated even without a periph-
eral stimulus ( 2). Pain is defi ned as chronic 
when it lasts beyond the expected healing 
time or over a 3-month-period (3). At this 
stage, chronic pain becomes disease itself, 
with substantial clinical, psychological, so-
cial and economic impact. 
n	 RELEVANCE OF 
 MUSCULOSKELETAL 
 CONDITIONS
Rheumatic diseases are a prominent cause 
of chronic pain ( 4). Musculoskeletal condi-
tions affect one in four adults across Europe 
(5). The MAPPING study, a cross-sectional 
epidemiological study analyzing the preva-
lence of musculoskeletal conditions in an 
Italian population sample, revealed that 
these conditions are common in the general 
adult population, particularly in women and 
with increasing age. The overall prevalence 
of musculoskeletal conditions was 26.7%. 
The most frequent diagnosis was symptom-
atic peripheral osteoarthritis (OA) (8.95%), 
followed by soft tissue disorders (8.81%), 
low back pain (5.91%), and infl ammatory 
rheumatic diseases (3.06%) (6). Recent 
estimates on the prevalence of rheumatic 
diseases indicate that in the United States 
nearly 27 million people are affected by 
clinical OA, 5 million have fi bromyalgia, 
up to 3 million have self-reported gout, 
rheumatoid arthritis affects 1.3 million 
adults, spondylarthritides from 0.6 to 2.4 
million adults (4). 
n	 EPIDEMIOLOGY AND 
 BURDEN OF 
 MUSCULOSKELETAL
 CHRONIC PAIN
Pain is almost constantly associated with 
musculoskeletal diseases. A review of prev-
alence studies indicates that almost one-fi fth 
of adult populations report widespread pain 
(fi bromyalgia), one-third shoulder pain and 
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up to one-half low back pain in a 1-month 
period (7). A survey on different health as-
pects in the European Union, the “Euroba-
rometer Report on Health” (1,8), included a 
question on musculoskeletal pain. As many 
as 32% of all respondents and 44% of those 
55 years and over reported to have experi-
enced muscle, joint, neck or back pain af-
fecting their daily activities in the previous 
week. Up to 25% of all respondents report-
ed chronic restrictive musculoskeletal pain 
lasting more than 3 months at some point in 
their life. A lower educational profile and 
female sex were risk factors for developing 
musculoskeletal pain (1,8). In 2008 a ques-
tionnaire conducted by the National Health 
and Wellness Survey on 53,525 adults in 
five European countries (United Kingdom, 
France, Spain, Germany and Italy) revealed 
that 22% of the subjects had suffered from 
pain within the last month, of whom 44% 
experienced pain daily (9). Back pain was 
the commonest condition causing chronic 
pain (71%), followed by joint pain, while 
oncologic pain accounted for only 1% of 
the patients. Pain severity correlated with 
the general health and mental status, with 
high incidence of depression (35%), anxi-
ety (42%) and sleep difficulties (58%) com-
pared to the general population (2, 9). 
The burden of chronic musculoskeletal pain 
is relevant, often leading to functional dis-
ability and potentially to severe impairment 
of normal daily living activities. About one 
third of the Italian population is reported 
to have sought medical advice for muscu-
loskeletal complaints in the previous year 
(10). OA is the most common joint disorder 
and accounts for more disability among the 
elderly than any other disease (1). Health 
related quality of life (HRQOL) of older 
patients with OA has been reported to be 
lower than that of the community-matched 
cohort and similar to scores from patients 
with depression or advanced cancer (1). 
OA is listed among the leading causes of 
burden of disease expressed in DALYs 
in Europe. One DALY can be defined as 
the loss of 1-year of healthy life. DALYs 
are calculated as the sum of the years of 
healthy life lost owing to premature mortal-
ity (YLL) and the years lived with disabil-
ity (YLD) (1). The MAPPING study evalu-
ating the quality of life in patients with 
musculoskeletal diseases demonstrated that 
severe chronic pain (grade III and IV), as-
sociated with high disability, was reported 
more commonly in the inflammatory rheu-
matologic diseases (22.7%), followed by 
the low back pain (12.6%) group, and was 
significantly lower in patients with osteo-
arthritis and soft tissue disorders (11). This 
study also demonstrated a significant cor-
relation between pain intensity and health 
status evaluated with the short form (SF-
36) questionnaire (11). 
n	 TREATMENT OVERVIEW:
 THE NEED FOR NEW 
 THERAPEUTICAL OPTIONS
From the previously mentioned evidence, it 
is clear that chronic pain has a substantial 
medical and social impact. Optimal man-
agement of OA requires a combination of 
non-pharmacological and pharmacological 
modalities. Initial treatment should focus 
on non-pharmacological approaches (eg, 
lifestyle, physical therapy). For patients 
whose symptoms are not controlled by 
these approaches, pharmacological treat-
ments should then be considered (12). 
Nevertheless, data focusing on the pharma-
cologic prescription modalities of general 
practitioners and specialists do not reflect 
the importance of an effective treatment of 
chronic pain.
An insight of the epidemiology of muscu-
loskeletal disorders in Italy revealed that at 
least 25% of the 48,136,832 Italians aged 
over 18 years (2006 census) report muscu-
loskeletal disorders, but nearly 40% don’t 
seek any medical attention and only 4% of 
them are followed by rheumatologists (13). 
The American Academy of Pain Medicine 
estimates that more than 4 every 10 patients 
with moderate-to severe pain don’t get ad-
equate relief from analgesics; a quarter of 
patients change health care professionals 
more than once because of perceptions of 
suboptimal pain care (14). Data from the 
AMICA study analysing pharmacologic 
and non-pharmacologic prescription pat-
terns of general practitioners and specialists 
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to treat symptomatic OA suggest that a con-
sistent number of patient don’t receive any 
treatment at all, while the majority of them 
are treated with mild analgesics, NSAIDs 
or coxibs (10). In the latest years, we are 
assisting to a decline in the use of NSAIDs 
to treat OA pain. This particularly affects 
elderly patients, in spite of the higher prev-
alence of musculoskeletal chronic pain in 
this population. The descending trend is 
probably due to the increasing awareness of 
potential side effects of NSAIDs, particu-
larly affecting the gastrointestinal system, 
in the setting of often multipathological, 
complex patients (15). A striking decrease 
in the use of coxibs was also registered af-
ter rofecoxib withdrawal from the market 
due to the evidence of an increased risk of 
myocardial infarction (16). An Italian study 
analysing the effect on drugs prescription 
after rofecoxib withdrawal showed a re-
duction in coxib use from 4.4% to 1.6%. 
A very low prevalence of weak opioids 
prescription (0.4%) was also reported (16). 
The American Geriatrics Society recom-
mendations suggest that acetaminophen 
should be the first choice pharmacotherapy 
in the elderly; NSAIDs and COX-2 selec-
tive inhibitors may be considered rarely, 
and with extreme caution, in highly se-
lected individuals. These patients should 
routinely be assessed for GI and renal tox-
icity, hypertension, heart failure. Patients 
with moderate to severe pain, pain-related 
functional impairment, or diminished qual-
ity of life because of pain should be consid-
ered for opioid therapy (17). Surprisingly, 
despite guidelines recommendations, the 
reduced prescription rate of anti-inflamma-
tory drugs was not followed by an increase 
in the use of different medications with 
proved efficacy, such as acetaminophen or 
weak opioids (15, 16).
The tendency to avoid opioid use in the 
treatment of musculoskeletal pain is not 
justified by published evidence. The ex-
pert consensus recommendations for the 
management of hip and knee OA (OARSI 
group) deriving from a systematic review 
of existing guidelines underlines, with high 
levels of evidence and consensus, that weak 
opioids can be considered for the treat-
ment of refractory pain, when other phar-
macological agents have been ineffective 
or are contraindicated. In exceptional cir-
cumstances stronger opioids could also be 
prescribed (12). A recent Cochrane review 
also reported some evidence of efficacy and 
function improvement in patients treated 
with opioids for chronic back pain (18). As 
previously mentioned, weak opioids can be 
a valid option also in the elderly patients at 
higher risk for anti-inflammatory-related 
adverse effects (17). 
The American Heart Association lists opi-
oids among medications with a more fa-
vourable safety profile, together with ac-
etaminophen, that should be preferred to 
NSAIDs and particularly coxibs, in patients 
with coronary artery disease (19). Opioids 
including tramadol represent a valid option 
after maximizing non-opioid pain relief 
strategies also in patients with back pain 
according to the American Pain Society 
guidelines (14). Opioids may also be ap-
propriate for patients with neuropathic pain 
who have not achieved adequate analge-
sia despite treatment with antineuropathic 
agents (eg anticonvulsants and tricyclic 
antidepressants/dual reuptake inhibitors) 
(14). Two systematic reviews of placebo-
controlled trials of opioids for non-cancer 
pain conditions (mainly OA and neuro-
pathic pain) found opioids to be moderately 
effective, with a mean decrease in pain in-
tensity with opioids of at least 30% in most 
trials (20). A meta-analysis of 18 clinical 
trials in OA patients including a total of 
3244 participants treated with opioids dem-
onstrated good efficacy in decreasing pain 
intensity and conferring modest functional 
benefits (21).
Great differences exist in analgesic pre-
scription among different European coun-
tries. Opioids are prescribed much more 
readily in Northern Europe compared to the 
South (including Italy) or the East, leading 
to the impression that pain treatment seems 
to be driven mainly by tradition and person-
al experience rather than by international 
guidelines (22). 
This “opiophobia” can partly be explained 
by the fear of adverse events induced by 
opioids. A systematic review and meta-
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analysis of 34 trials including 4212 patients 
provided information on adverse events 
related to opioid use in treating musculo-
skeletal pain. About one patient every two 
experienced at least one adverse event, and 
one in five discontinued treatment because 
of adverse events. Nausea (21%), constipa-
tion (15%), dizziness (14%), and drowsi-
ness or somnolence (14%) were the most 
common (23). A recent review on potential 
adverse effects of long-term opioid therapy 
(24) confirmed that gastrointestinal (GI) 
side effects are the most common ones. Up 
to 40%-45% of patients on opiate therapy 
experience constipation, while 25% experi-
ence nausea. 
Opioid neurotoxicity, dizziness and se-
dation are a significant issue, especially 
among the elderly. Other possible adverse 
reactions are: association between sleep-
disordered breathing and chronic opiate 
use in a dose-dependent fashion, opiate-
induced hypogonadism, and possible nega-
tive cardiovascular effects such as increased 
risk of myocardial infarction or heart fail-
ure, as well as increased pneumonia risk 
among the elderly, possibly associated 
with immunosuppression (24). Tolerance 
and addiction are also relevant issues when 
prescribing opioids. Risk factors for opioid 
abuse are history of previous drug convic-
tion, mental health disorders, past alcohol 
or illicit drug abuse (25). Moreover, opioid 
treatment may not be effective because of 
individual variations to pure μ-opioid ago-
nist therapies and different degrees of cen-
tral sensitization. In chronic musculoskel-
etal pain conditions descending inhibitory 
pain pathways may be disrupted and drugs 
with different mechanisms of action (eg, 
serotonin or noradrenalin reuptake inhibi-
tion) may be more effective, compared to 
pure μ-opioid receptor agonists (26-27).   
The previous results suggest that efficacy 
and tolerability problems are encountered 
with all therapeutic strategies available to 
treat musculoskeletal pain. This often limits 
effective analgesia and patients’ long term 
compliance, with the result that chronic 
pain is persistently undertreated. The need 
for new therapeutic options is therefore 
stringent. 
n	 TAPENTADOL
Tapentadol is a novel, centrally acting an-
algesic that has been recently commercial-
ized. This new molecule, by combining two 
distinct mechanisms of action, μ-opioid re-
ceptor agonism (MOR) and noradrenaline 
reuptake inhibition (NRI), introduces a new 
pharmacological class called MOR-NRI 
(28). The synergistic interaction of the two 
combined effects offers particular advan-
tages in terms of efficacy and tolerability. 
Analgesia is obtained at different levels 
through modulation of the opioid system 
and the descending inhibitory noradrener-
gic systems. The NRI mechanism of action 
leads to increased noradrenergic activity at 
the spinal level, through activation of the 
inhibitory descending pathways where nor-
adrenaline is an important transmitter. The 
MOR therapeutic effect enhances the action 
of opioids at the spinal level, where they re-
duce the transmission of pain signal from 
the primary afferents to the spinothalamic 
tract fibers. At a supraspinal level, opioids 
contribute to activate the descending norad-
renergic inhibitory projection to the spinal 
cord (29). Indeed, several preclinical pain 
models demonstrate that, despite a 50-fold 
lower affinity for the MOR, tapentadol is 
only 2- to 3-fold less potent than morphine, 
clearly indicating that the NRI component 
of tapentadol contributes to its analgesic 
effect in an additive and synergistic man-
ner (30). The two mechanisms of action 
result in different modulation of acute and 
chronic pain. The μ-opioid agonism is, in 
fact, primarily effective in controlling acute 
pain, whereas noradrenaline reuptake inhi-
bition is mainly implicated in modulating 
chronic pain (2). The efficacy of tapentadol 
in neuropathic pain conditions has been 
demonstrated in a number of experimental 
models. In this setting, tapentadol shows 
even higher potency than morphine (ED50 
=0.32 mg/kg vs 0.65 mg/kg in diabetic neu-
ropathy) (30). The inhibitory effect on dis-
ease-related hyperalgesia suggested a supe-
rior efficacy profile of tapentadol compared 
with classical opioid, including morphine, 
in a rodent animal model of heat hyperalge-
sia (31). Efficacy on neuropathic pain has 
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also been reported in clinical studies, espe-
cially in controlling chronic back pain with 
radicular involvement (32) and diabetic 
neuropathy (33). The MOR-NRI mecha-
nism of action can finally give advantages 
in terms of tolerability. Tapentadol’s norad-
renergic components has an opioid-sparing 
effect, thus reducing GI adverse effects 
compared to traditional opioids. This new 
molecule also has minimum effect on se-
rotonin reuptake, reducing its effects on 
the enteric nervous system (constipation, 
nausea and vomiting) (2). The safety pro-
file is improved by the fact that no relevant 
interactions with enzymes of the P450 cy-
tochrome system have been registered. The 
drug binding to plasma protein is low, re-
ducing pharmacokinetic interaction with 
other medications (2). 
Randomized clinical trials (RCT) have 
consistently demonstrated the efficacy and 
tolerability of tapentadol prolonged release 
(PR) (100-250 mg bid) in the management 
of moderate to severe chronic pain caused 
by OA and low back pain. (Table I). A meta-
nalysis on efficacy data (34) was performed 
using results from 3 RCT of tapentadol PR 
(100-250 mg bid) compared with placebo 
and oxycodone controlled release (20-50 
mg bid) in the treatment of OA knee pain 
(35) and chronic low back pain (36). Tape-
natodol PR analgesic efficacy resulted to be 
non-inferior to that provided by oxycodone 
(20-50 mg bid) (p<0.0001), but with a more 
favourable tolerability profile, particularly 
regarding GI adverse events (lower rates of 
nausea, vomiting, constipation) and central 
nervous system side effects. Also the anal-
yses of 30% and 50% responders, patient 
global impression of change, Short-Form- 
36 scores (SF-36) and the EuroQol 5-di-
mension health status index (EQ-5D) were 
all significantly improved with tapentadol 
compared to oxycodone (p≤0.048) (35). 
Figure 1 and 2. 
Comparable results were recently reported 
by Afilafo et al. (37), confirming the effi-
cacy of tapentadol ER for different types 
of nociceptive (chronic osteoarthritis knee 
pain and low back pain) and neuropathic 
pain (diabetic peripheral neuropathy) over 
up to one year of treatment, maintaining a 
better tolerability profile compared to oxy-
codone. 
Another recent phase 3b study evaluated 
the effectiveness and tolerability of tapen-
tadol PR, associated with tapentadol imme-
diate release on-demand, for severe chronic 
OA knee pain, inadequately managed with 
WHO step I or II analgesics (38). A sig-
nificant improvement in pain intensity from 
baseline through week 1 was demonstrated 
(p<0.0001). Responder rate (the percent-
age of patients with a decrease in aver-
age pain intensity of ≥1 point on a NRS-3 
scale: 11-point numerical rating scale rang-
ing 0-10) was 96.9%, associated with high 
satisfaction ratings. All the subscale scores 
and the global score of the WOMAC (West-
ern Ontario and McMaster Universities 
osteoarthritis index), a self-administered 
questionnaire used to assess pain, dis-
ability and joint stiffness in knee and hip 
OA, significantly improved from baseline 
to weeks 6,8, and 12. Quality of life was 
also improved by tapentadol treatment, as 
demonstrated by significantly improved 
scores in the EQ-5D and SF-36 physical 
and mental components. Significant reduc-
tion of anxiety and depression reported by 
patients were also recorded (39). Side ef-
fects were reported by 71% of patients 
(leading to study discontinuation in 12.5% 
of patients). The majority of adverse events 
(95.7%) were considered to be of mild or 
moderate intensity, mainly affecting the GI 
system (39). 
Tapentadol proved to be effective also in 
the management of neuropathic pain in the 
setting of severe chronic low back pain that 
was inadequately managed with WHO step 
I and II analgesics (39).
Significant improvements in pain intensity 
and neuropathic pain symptoms have been 
observed on an open-label, phase 3 study 
analyzing the effect of tapentadol vs strong 
opioids in the management of chronic 
low back pain (33). Patients responding 
to WHO step III opioids, but with scarce 
tolerability, were selected to receive tapen-
tadol PR. Pain relief was comparable to 
equianalgesic doses of strong opioids, but 
with improved tolerability. Neuropathic 
pain component of low back pain was as-
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Table I - Main RCT evaluating the role of tapentadol in managing chronic musculoskeletal pain (OA and LBP) (32, 34-38, 46).
Author, year Type of 
study
No. Cause of 
chronic pain
Control 
group
Study 
period
Results Discontinuation 
due to AE
Afilafo, 
2010*
Multicentre, 
double blind, 
phase III
1023 OA knee pain Oxycodone, 
placebo
15 wks - ≥50% improvement of pain 
 intensity in 32% for TP PR 
 vs 24.3% for OX CR (p=0.027)
19,2% TP PR 
vs 42,7% OX CR
(GI 43% vs 67,3%)
NCT00486811* Double blind 
randomized 
phase III
987 OA knee pain Oxycodone, 
placebo
15 wks - Differences in reduction 
 of pain intensity not statistically 
significant between TP PR, 
 OX CR and placebo
18,8% TP PR 
vs 40,7% 
OX CR
Buynak, 
2010*
Prospective, 
randomized, 
double-blind, 
phase III study
981 OA knee pain Oxycodone, 
placebo
15 wks - Reduction in pain intensity 
 (-2.9 for TP PR and OX CR 
 vs -2.1 for placebo) p<0.001
- Lower incidence of AE
16.7% TP PR 
vs 31.7% OX CR
(GI 43.7% 
vs 61.9% 
OX CR)
Wild, 2010 Open label, 
phase III
1117 OA knee 
or hip pain 
and LBP
Oxycodone 52 wks - Sustained long-term efficacy
- Better GI tolerability
22.1% TP PR 
vs 36.8% OX 
CR (GI 8.6% 
vs 21.5%)
Steigerwald, 
2012
Open-label, 
phase IIIb
224 OA knee pain WHO step I 
or II analgesics
7 wks - Responder rate: 96.9%
- Satisfaction rate: up to 92%
- Improvement in WOMAC
 scores (p<0.0001)
- Improved SF-36 (p<0.05)
12.5%
(nausea, 
constipation)
Gàlvez, 2013 Multicenter, 
multinational, 
open-label, 
phase IIIb
342 Chronic 
back pain
(+/-neuropathic) 
with poor 
tolerability
to previous 
opioids
Strong opioids 12 wks - Responder rate: 80.9%. 
- Satisfaction rate up to 82.8%
- Reduction of PainDETECT 
 score (p<0.05)
- Improved SF-36 (p<0.05)
- Comparable pain relief 
- Improved tolerability 
14.4%
(nausea, 
vomiting, 
dizziness)
Baron, 2015 Multicenter, 
multinational, 
open-label, 
phase IIIb
288 LBP with a 
neuropathic 
component
TP PR lower 
dose + 
Pregabalin
8 wks - Effectiveness non inferior to
 control group
- Mean pain intensity 
 decreased –3.9 vs –4.3
- PainDETECT –9.7 vs –10.9
- Lower dizziness/somnolence
 16.9% vs 27%
51%
(serious AE 
3.2% vs 1.9%)
Baron, 2015 Multicenter, 
open label, 
phase IIIb trial, 
continuation 
arm
309 LBP with a 
neuropathic 
component 
having reached 
pain control 
with TP PR 
300 mg/day 
(continuation 
arm)
TP 500 mg/
day or TP PR 
+ pregabalin 
(comparative 
arm) for  
patients 
who had not 
adequately 
responded  
to TP PR 
300 mg/day
8 wks - Mean pain intensity improved  
(mean change: - 5.3 continuation 
arm; - 2.5 comparative arm)
- Patient global impression to 
 change: 94.9%
- Improved quality of life (SF-12), 
anxiety and depression scales.
- PainDETECT: mean change:
 -12.3 (continuation arm); 
 -4.6; -5.1 for comparative arm)
50.8%, leading 
to discontinuation 
in 5.1% (nausea, 
vomiting, 
headache, 
nervousness, 
restlessness)
OA= osteoarthritis, LBP= low back pain. TP PR = tapentadol prolonged release (50-250 bid). OX CR = oxycodone controlled release 
(20-50 bid). AE = adverse events, GI = gastrointestinal side effects. *Pooled analysis by Lange et al., 2010.
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Figure 1 - Patient 
global impression of 
change at endpoint. 
Statistically signifi-
cant difference of Pa-
tient Global Impres-
sion of Change for 
tapentadol and oxy-
codone compared to 
placebo (p<0.001). 
Modified from Lange 
et al. (34).
Figure 2 - Treatment 
emergent adverse 
events. 
Data from Pooled 
analysis by Lange 
et al (34). Significant 
lower incidence of 
GI adverse events in 
the tapentadol group 
compared to oxyco-
done (p<0.001). 
Gastroint. = gastroin-
testinal side effects.
sessed using the painDETECT question-
naire or the Neuropathic Pain Symptom 
Inventory (NPSI). PainDETECT is a highly 
sensitive tool that addresses frequency and 
quality of neuropathic pain symptoms, pain 
patterns over time and radiating pain (33, 
40). The Neuropathic Pain Symptom In-
ventory (NPSI) is a validated measure ad-
dressing different qualities of spontaneous, 
ongoing or paroxysmal pain, evoked pain 
and dysesthesia or paresthesia together 
with frequency and duration of pain (33, 
41). Both painDETECT and NPSI signifi-
cantly improved with tapentadol treatment. 
In line with previous studies, also measures 
of quality of life, health status, function and 
patient satisfaction increased substantially 
(33). In 2015, a Cochrane review analysed 
the available evidence concerning the use 
of Tapentadol for chronic musculoskeletal 
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pain in adults. The authors included data on 
4094 patients with LBP and/or OA enrolled 
in several RCTs. All trials were oxycodone-
controlled and sometimes accepted the use 
of placebo. When compared to placebo, TP 
PR demonstrated a mean reduction of 0.56 
points (95% CI 0.92-0.2) on a 11-point-
NRS scale at 12 weeks of follow up, with 
a 36% probability of responding to treat-
ment. The risk of discontinuation due to 
side effects during treatment with TP PR 
increased of 2.7 fold. In the oxycodone-
controlled analyses, TP PR showed a 0.24 
points (95% CI 0.43-0.05) reduction in 
pain intensity. The possibility to respond 
to treatment did not reach statistical signifi-
cance. The high heterogeneity of the effi-
cacy estimates may account for some of the 
suboptimal results. Nevertheless, TP PR 
confirmed the good tolerability profile with 
a 50% reduction in the risk of discontinua-
tion due to side effects and a 9% reduction 
in the overall adverse events occurrence 
risk compared to oxycodone (42). 
Ongoing studies with promising results are 
also exploring the use of Tapentadol in the 
management of fibromyalgia not respond-
ing to standard therapy. 
Long term safety of tapentadol in the treat-
ment of chronic OA and low back pain has 
been evaluated for up to one year in a Phase 
III, open-label, randomized study including 
1117 patients (43). Patients were random-
ized 4:1 to receive tapentadol PR or oxy-
codone CR. Tapentadol provided stable, 
long-term relief from chronic pain and was 
associated with significantly lower levels of 
constipation (22.6% vs 38.6%; p<0.001), 
nausea (18.1% vs 33.2%; p<0.001), and 
vomiting (7.0% vs 13.5%; p=0.002) com-
pared to oxycodone. GI side effects led to 
study discontinuation in 8.6% and 21.5% of 
patients respectively (44). Tapentadol also 
showed minimal effects on adrenal, pitu-
itary, hypothalamic and gonadal hormone 
production with lower rates of opioid-
induced androgen deficiency compared to 
other μ-opioid analgesics (2).
A high level of concern exists for the risk 
of abuse and diversion connected with opi-
oids. In the United States opioids addiction 
and abuse is regarded as a major public 
health issue and is monitored through the 
Research Abuse, Diversion, and Addiction-
Related Surveillance (RADARS) System. 
During the first 24 months following its 
introduction, Tapentadol immediate release 
(IR) showed a particularly favorable pro-
file, with lower rates of abuse and diversion 
compared to oxycodone and hydrocodone 
(44,45). Budget impact analysis of tapen-
tadol PR for the treatment of moderate to 
severe chronic non-cancer pain have also 
showed a favourable economic profile driv-
en by lower drug costs and daily average 
consumption and fewer opioid induced side 
effects (46).
n	 CONCLUSIONS
Musculoskeletal conditions are the most 
frequent cause of chronic pain and af-
fect around 1 in 5 adults in Europe. When 
chronic pain occurs, it becomes disease it-
self, with substantial clinical, psychologi-
cal, social and economic impact. Pain is 
too often underestimated and inadequately 
treated; this is mainly due to tolerability 
problems connected with traditional anal-
gesics and unjustified low prescription rates 
of opioids. Recently Tapentadol, a novel, 
centrally acting analgesic has been intro-
duced for the treatment of chronic pain. 
This new molecule, by combining two 
distinct mechanisms of action, μ-opioid re-
ceptor agonism (MOR) and noradrenaline 
reuptake inhibition (NRI), introduces a new 
pharmacological class called MOR-NRI. 
Tapentadol has shown promising results 
in the management of both nociceptive 
and neuropathic pain and good tolerabil-
ity profile, particularly concerning GI side 
effects, compared to traditional opioids. 
Several studies have led to consistent and 
reproducible results on efficacy and toler-
ability profile of tapentadol, regardless of 
the type of chronic pain, study population, 
and methodological differences. This ver-
satility is enabled by a molecule without 
active metabolites and a double mecha-
nisms of action. This novel analgesic rep-
resents a possible therapeutic option also 
in the rheumatologic field, particularly in 
the treatment of osteoarthritis and low back 
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pain. Further studies are needed to assess 
the role of tapentadol in the management of 
pain connected with inflammatory arthritis 
or caused by vasculitis.
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